Ascendis Pharma A/S
No enriched coverage for $ASND in the last 7 days.
No SEC Form 4 filings for $ASND in the last 30 days.
See all $ASND insider activity →Artisan Partners’ Artisan Small Cap Fund Q2 2026 investor letter said the fund returned 26.02% (Investor Class ARTSX), modestly ahead of the Russell 2000 Growth Index’s 25.71%. The letter highlighted Ascendis Pharma A/S (NASDAQ:ASND), noting mixed results, YORVIPATH patient growth, and a position trim after a competitor lawsuit. ASND closed at $252.66 on July 23, 2026.
Vertex (VRTX) agreed to acquire Crinetics (CRNX) for about $10B, or $85.00 per share in all cash, approved by both boards and expected to close in Q3 2026. CRNX shares rose about 99% to ~$83.54. Vertex projects the endocrine franchise could exceed $5B peak annual sales. Peers NBIX and CORT also gained on M&A expectations.
Ascendis Pharma said it will present results at the 2026 International Conference on Children’s Bone Health in Montreal from its pivotal ApproaCH trial of YUVIWEL and its ongoing Phase 2 COACH trial of YUVIWEL plus SKYTROFA in children with achondroplasia. ApproaCH (84 children) showed a Week 52 growth-velocity treatment difference vs placebo of 1.78 cm/year and mean annualized growth velocity of 5.71 cm/year through Week 104 in ages 5+. COACH Week 52 reported 8.80 cm/year (treatment-naïve) and
Recent ASND coverage spans insider activity, financial news and mergers & acquisitions.
Near-term sentiment risk from lawsuit distraction, partially offset by continued patient growth and share gains for key therapies.
ASND’s reaction is framed as sector read-through, implying limited incremental information for trading beyond sentiment.
Conference-bound clinical data and ongoing combination-therapy readout can shift expectations for YUVIWEL durability and COACH differentiation, supporting sentiment and near-term trading interest.
This is a small insider open-market buy by the CFO, which can be mildly supportive but is unlikely to change fundamentals or guidance.
Insider buying can be interpreted as confidence, but this is a small, routine-sized purchase with limited standalone signal.
alphai scores every news story that mentions ASND with an AI model for sentiment and relevance, and aggregates insider trades from Ascendis Pharma A/S's SEC EDGAR Form 4 filings. Figures refresh continuously.
Artisan Partners’ Artisan Small Cap Fund Q2 2026 investor letter said the fund returned 26.02% (Investor Class ARTSX), modestly ahead of the Russell 2000 Growth Index’s 25.71%. The letter highlighted Ascendis Pharma A/S (NASDAQ:ASND), noting mixed results, YORVIPATH patient growth, and a position trim after a competitor lawsuit. ASND closed at $252.66 on July 23, 2026.
6 min readVertex (VRTX) agreed to acquire Crinetics (CRNX) for about $10B, or $85.00 per share in all cash, approved by both boards and expected to close in Q3 2026. CRNX shares rose about 99% to ~$83.54. Vertex projects the endocrine franchise could exceed $5B peak annual sales. Peers NBIX and CORT also gained on M&A expectations.
7 min readAscendis Pharma said it will present results at the 2026 International Conference on Children’s Bone Health in Montreal from its pivotal ApproaCH trial of YUVIWEL and its ongoing Phase 2 COACH trial of YUVIWEL plus SKYTROFA in children with achondroplasia. ApproaCH (84 children) showed a Week 52 growth-velocity treatment difference vs placebo of 1.78 cm/year and mean annualized growth velocity of 5.71 cm/year through Week 104 in ages 5+. COACH Week 52 reported 8.80 cm/year (treatment-naïve) and
4 min readSMITH SCOTT THOMAS (EVP & Chief Financial Officer) purchased 100 shares of Ascendis Pharma A/S (ASND) at $219.00 on 2026-06-02.
2 min readBIENAIME JEAN JACQUES purchased 100 shares of Ascendis Pharma A/S (ASND) at $223.50 on 2026-05-29.
1 min readBIENAIME JEAN JACQUES purchased 200 shares of Ascendis Pharma A/S (ASND) at $222.30 on 2026-05-29.
2 min readBIENAIME JEAN JACQUES purchased 200 shares of Ascendis Pharma A/S (ASND) at $223.76 on 2026-05-29.
2 min readSMITH SCOTT THOMAS (EVP & Chief Financial Officer) purchased 250 shares of Ascendis Pharma A/S (ASND) at $223.32 on 2026-05-29.
2 min readBIENAIME JEAN JACQUES purchased 200 shares of Ascendis Pharma A/S (ASND) at $236.24 on 2026-05-26.
1 min readAscendis Pharma (ASND) announced it will report its first-quarter 2026 financial results and provide a business update on May 7, 2026, before the U.S. market opens. The company will also host a conference call and live webcast at 8:00 a.m. ET to discuss these results. A replay of the webcast will be available for 30 days after the event on the Investors & News section of their website.
3 min read
